Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer

CHIHIRO ANDO, EIKI ICHIHARA, HIROHISA KANO, YOSHITAKA IWAMOTO, ATSUKO HIRABAE, TAKAMASA NAKASUKA, YOSHINOBU MAEDA and KATSUYUKI KIURA
In Vivo November 2019, 33 (6) 2113-2115; DOI: https://doi.org/10.21873/invivo.11711
CHIHIRO ANDO
1Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EIKI ICHIHARA
1Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ichiha-e@md.okayama-u.ac.jp
HIROHISA KANO
2Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHITAKA IWAMOTO
2Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUKO HIRABAE
1Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAMASA NAKASUKA
2Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHINOBU MAEDA
2Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUYUKI KIURA
1Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Atypical tumor responses such as pseudo-progression or hyper-progression sometimes occur during immune check point inhibitor therapy. Distinct from both responses, we experienced a case of non-small cell lung cancer (NSCLC) with a pseudo-relapse, in which development of granulation mimicked cancer relapse during nivolumab therapy. A male with advanced NSCLC started nivolumab as a second-line therapy. After 15 cycles of nivolumab with a complete response, tumor markers started increasing and positron-emission computed tomography indicated a hot spot in the sigmoid colon. Laparoscopic segmental sigmoid colon resection revealed granulation tissue without any relapse of malignant cells. The results showed that even if radiographical tumor progression is found during immune therapy, histological confirmation should be considered.

  • Lung cancer
  • immune checkpoint inhibitors
  • nivolumab
  • granulation tissue

Over the past several years, immune check point inhibitors (ICIs) such as anti-programmed cell death protein 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies have dramatically changed systemic therapy for solid tumors, including non-small cell lung cancer (NSCLC). Nivolumab is an anti-PD-1 antibody that was approved as the first ICI for advanced NSCLC (1), followed by the development of pembrolizumab and atezolizumab. It is noteworthy that these ICIs can potentially cure advanced solid tumors. Traditionally, disease progression during systemic therapy has been determined with imaging, including computed tomography; now, however, with the use of ICIs, atypical tumor responses such as pseudo-progression (2) often occur, which makes it difficult to determine disease progression using only imaging. When considering potential cures and atypical responses, histological confirmation is becoming more important for determining disease progression.

We report a case of NSCLC with complete remission (CR) using nivolumab, which was accompanied by pseudo-relapse due to granulation tissue. In this case, diagnosis of pseudo-relapse would not have been determined without histological examination.

Case

A 60-69-year-old male was diagnosed with unresectable pulmonary adenocarcinoma in April 2016 (Figure 1A). Initially, he received cisplatin and pemetrexed with a maximum partial response (PR), followed by subsequent disease progression. Nivolumab, started as second-line therapy in April 2017, significantly inhibited tumor growth, resulting in CR. After 15 cycles of nivolumab, serum carcinoembryonic antigen (CEA) levels started increasing and fluorode-oxyglucose (FDG) positron-emission computed tomography demonstrated marked FDG accumulation in localized abdominal lesions (Figure 1B, circled). Colonoscopy revealed a tumor in the sigmoid colon, and biopsy from the lesion showed only granulation tissue. Because the sigmoid lesion could be metastatic lung cancer and there was no other active lesion, he underwent sigmoidectomy for the purpose of diagnosis and radical therapy. Laparoscopic segmental sigmoid colon resection revealed a tumor penetrating from inside to the outside of the intestinal wall (Figure 2A). Histopathology revealed that the resected tumor developed beside a colon diverticulum and consisted of granulation tissue without any malignancy (Figure 2B).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Fluorodeoxyglucose (FDG) positron-emission computed tomography (PET) image. A) Before nivolumab treatment, B) after nivolumab.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Macroscopic and microscopic images of the resected tumor. A) Macroscopic image of the resected tumor, B) Histology of the resected tumor. Food debris is recognized inside the granulation tissue.

The patient had been treated with nivolumab for more than 1 year, without any recurrence, since the sigmoidectomy.

Discussion

We describe a case of NSCLC with a pseudo-relapse caused by granulation tissue during nivolumab treatment. To the best of our knowledge, there has been no other study reporting that granulation tissue mimics progression of NSCLC during ICI treatment.

Although a granuloma is totally different from granulation tissue, there are several reported cases that a granuloma, such as a sarcoid reaction, mimics tumor progression during treatment with ICIs (3-6). In many of these studies, a granuloma was histologically proven by enlarged lymph nodes, which spontaneously regressed. In our case, the colon lesion revealed no granuloma and did not regress for 6 months until surgery.

A diverticulum existed next to the granulation tissue, suggesting that a strongly activated immune reaction to diverticulitis might have occurred due to nivolumab, resulting in the formation of the granulation tissue. In addition, elevated CEA, which prompted us to suspect a tumor relapse, further increased transiently after the sigmoidectomy, followed by a subsequent decrease. Although the precise reason for elevated CEA remains unclear, it may have resulted from strong immunogenic inflammation. It is known that CEA increases due to benign inflammatory diseases such as pneumonia (7) as well as malignancy.

Because there is a chance of a potential cure with ICIs, even in advanced NSCLC (1) and, given that there are certain atypical responses to ICIs including pseudo-progression (2) and sarcoid reaction (8), we should asses tumor progression carefully and cautiously. Even if tumor progression is radiographically found, histological confirmation should be conducted.

Footnotes

  • Authors' Contributions

    Writing, review, and/or revision of the manuscript: Ichihara E; Writing and/or review: Ando C, Kano H, Iwamoto Y, Hirabae A, Nakasuka T, Maeda Y, Kiura K.

  • This article is freely accessible online.

  • Conflicts of Interest

    There is no conflict of interest to declare regarding this study.

  • Received July 20, 2019.
  • Revision received August 13, 2019.
  • Accepted September 14, 2019.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Borghaei H,
    2. Paz-Ares L,
    3. Horn L,
    4. Spigel DR,
    5. Steins M,
    6. Ready NE,
    7. Chow LQ,
    8. Vokes EE,
    9. Felip E,
    10. Holgado E,
    11. Barlesi F,
    12. Kohlhaufl M,
    13. Arrieta O,
    14. Burgio MA,
    15. Fayette J,
    16. Lena H,
    17. Poddubskaya E,
    18. Gerber DE,
    19. Gettinger SN,
    20. Rudin CM,
    21. Rizvi N,
    22. Crino L,
    23. Blumenschein GR Jr..,
    24. Antonia SJ,
    25. Dorange C,
    26. Harbison CT,
    27. Graf Finckenstein F,
    28. Brahmer JR
    : Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17): 1627-1639, 2015. PMID: 26412456. DOI: 10.1056/NEJMoa1507643
    OpenUrlCrossRefPubMed
  2. ↵
    1. Fujimoto D,
    2. Yoshioka H,
    3. Kataoka Y,
    4. Morimoto T,
    5. Hata T,
    6. Kim YH,
    7. Tomii K,
    8. Ishida T,
    9. Hirabayashi M,
    10. Hara S,
    11. Ishitoko M,
    12. Fukuda Y,
    13. Hwang MH,
    14. Sakai N,
    15. Fukui M,
    16. Nakaji H,
    17. Morita M,
    18. Mio T,
    19. Yasuda T,
    20. Sugita T,
    21. Hirai T
    : Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. J Thorac Oncol 14(3): 468-474, 2019. PMID: 30468872. DOI: 10.1016/j.jtho.2018.10.167
    OpenUrl
  3. ↵
    1. Birnbaum MR,
    2. Ma MW,
    3. Fleisig S,
    4. Packer S,
    5. Amin BD,
    6. Jacobson M,
    7. McLellan BN
    : Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep 3(3): 208-211, 2017. PMID: 28443311. DOI: 10.1016/j.jdcr.2017.02.015
    OpenUrl
    1. Lainez S,
    2. Tissot C,
    3. Cottier M,
    4. Vergnon JM
    : Ebus-tbna can distinguish sarcoid-like side effect of nivolumab treatment from tumor progression in non-small cell lung cancer. Respiration 94(6): 518-521, 2017. PMID: 28910804. DOI: 10.1159/000480155
    OpenUrl
    1. Noguchi S,
    2. Kawachi H,
    3. Yoshida H,
    4. Fukao A,
    5. Terashita S,
    6. Ikeue T,
    7. Horikawa S,
    8. Sugita T
    : Sarcoid-like granulomatosis induced by nivolumab treatment in a lung cancer patient. Case Rep Oncol 11(2): 562-566, 2018. PMID: 30186140. DOI: 10.1159/000492383
    OpenUrl
  4. ↵
    1. Paolini L,
    2. Poli C,
    3. Blanchard S,
    4. Urban T,
    5. Croue A,
    6. Rousselet MC,
    7. Le Roux S,
    8. Labarriere N,
    9. Jeannin P,
    10. Hureaux J
    : Thoracic and cutaneous sarcoid-like reaction associated with anti-pd-1 therapy: Longitudinal monitoring of pd-1 and pd-l1 expression after stopping treatment. J Immunother Cancer 6(1): 52, 2018. PMID: 29898781. DOI: 10.1186/s40425-018-0372-4
    OpenUrl
  5. ↵
    1. Marechal F,
    2. Berthiot G,
    3. Deltour G
    : Serum levels of ca-50, ca-19.9, ca-125, ca-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung. Anticancer Res 8(4): 677-680, 1988. PMID: 3178158.
    OpenUrlPubMed
  6. ↵
    1. Gkiozos I,
    2. Kopitopoulou A,
    3. Kalkanis A,
    4. Vamvakaris IN,
    5. Judson MA,
    6. Syrigos KN
    : Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 13(8): 1076-1082, 2018. PMID: 29763666. DOI: 10.1016/j.jtho.2018.04.031
    OpenUrl
PreviousNext
Back to top

In this issue

In Vivo: 33 (6)
In Vivo
Vol. 33, Issue 6
November-December 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer
CHIHIRO ANDO, EIKI ICHIHARA, HIROHISA KANO, YOSHITAKA IWAMOTO, ATSUKO HIRABAE, TAKAMASA NAKASUKA, YOSHINOBU MAEDA, KATSUYUKI KIURA
In Vivo Nov 2019, 33 (6) 2113-2115; DOI: 10.21873/invivo.11711

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer
CHIHIRO ANDO, EIKI ICHIHARA, HIROHISA KANO, YOSHITAKA IWAMOTO, ATSUKO HIRABAE, TAKAMASA NAKASUKA, YOSHINOBU MAEDA, KATSUYUKI KIURA
In Vivo Nov 2019, 33 (6) 2113-2115; DOI: 10.21873/invivo.11711
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
  • Google Scholar

More in this TOC Section

  • Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study
  • Pediatric Patients With Sickle Cell Disease at a Public Hospital: Nutrition, Compliance and Early Experience With L-Glutamine Therapy
  • Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years
Show more Clinical Studies

Similar Articles

Keywords

  • lung cancer
  • immune checkpoint inhibitors
  • nivolumab
  • granulation tissue
In Vivo

© 2022 In Vivo

Powered by HighWire